Skip to main content
Caplight Logo









Nimbus Therapeutics

Nimbus Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.nimbustx.com/

Last Round

VC Round

Sep 6, 2023

Total Funding Raised

$68.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nimbus Therapeutics is a biotechnology company that develops small molecule compounds aimed at discovering innovative medicines and enhancing drug development for metabolic diseases, cancer, and immune-inflammatory disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

computational drug discoverysmall-molecule therapeuticsdrug discovery platformAI drug discoveryin silico drug designundruggable targetsbiotech licensingstructure-based designclinical-stage biotechtranslational medicinecomputational chemistrypredictive modelingpharma R&Dgenerative AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nimbus Therapeutics Comparables

Compare Nimbus Therapeutics with similar companies based on industry and business-model similarity.

Nimbus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Antares Therapeutics
85%
Insitro
83%
HotSpot Therapeutics
83%

Nimbus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 6, 2023
VC RoundSep 12, 2022
VC RoundJul 13, 2021
VC RoundOct 14, 2020
VC RoundJun 5, 2018
Series B
Mar 18, 2015

Key People

Founding team and executive leadership

Holly Whittemore

CFO

Executive Team

Ian Sanderson

Chief Financial Officer

Executive Team

Nimbus Therapeutics Investors

Notable investors and investment history

Nimbus Therapeutics investors
InvestorRounds
Surveyor CapitalVC Round
Access IndustriesVC Round
Bain Capital Life SciencesVC Round
RA Capital AdvisorsVC Round
RA Capital ManagementVC Round
SV Health InvestorsVC Round
GVVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Presenting new data on SIK2 inhibitor program at IMMUNOLOGY2026.

  • Mar 31, 2026

    Announced new SIK2 inhibitors for autoimmune diseases, cancer, and diabetes.

Nimbus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nimbus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nimbus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range100
Year Founded2009
Last FundingSep 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?